CompletedEarly Phase 1

NeuroGlove PD Study Clinical

United States8 participantsStarted 2024-08-22

Plain-language summary

Safety and Feasibility of Peripheral Sensory Stimulation of the Hand in the Treatment of Parkinson's Disease

Age range18 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Able to and willing to provide informed consent. Legally authorized representatives (LARs) will not be allowed to consent on behalf of the subject.
✓. Men and women ≥18 and \<85 years of age.
✓. Carry an active diagnosis of PD
✓. Suffer from PD symptoms that impact subject's daily activities and quality of life

✕. Physical limitations of the upper extremity (e.g., fracture, joint deformity, severe spasticity/contracture, wounds, skin breakdown, lymphedema, etc.)
✕. Lacks the ability to comprehend or follow instructions, or for any reason, in the opinion of the investigator, would be unlikely or unable to comply with study protocol requirements.
✕. Currently participating in another interventional clinical trial (observational clinical trial participation is allowed for study enrollment.)

Use the UPDRS to Evaluate safety and feasibility of device

Timeframe: 4 weeks

Use Custom Satisfaction Scale to Rate and severity of adverse events related to the use of the NeuroGlove.

Timeframe: 4 weeks

NCT IDNCT06578273

SponsorNeuroGlove LLC

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2024-08-22